title: Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives.
abstract: Luminal breast cancer, as defined by oestrogen and/or progesterone expression by immunohistochemistry, accounts for up to 75% of all breast cancers. In this population, endocrine therapy is likely to account for most of the gains obtained with the administration of adjuvant systemic treatment. The role of adjuvant chemotherapy in these patients remains debatable since it is known that only a small fraction of patients will derive meaningful benefit from this treatment whilst the majority will be exposed to significant and unnecessary chemotherapy-related toxicities, in particular the elderly and frail. Therefore, neoadjuvant endocrine therapy (NET) becomes an attractive option for selected patients with hormonal-receptor positive locally advanced breast cancer. In this review, we discuss the current role of NET and future perspectives in the field.
authors.affiliation: Instituto do Câncer do Estado de São Paulo (ICESP), Faculdade de Medicina, Universidade de São Paulo, Av Dr Arnaldo, 251, 5o andar, 01246-000 São Paulo, SP, Brazil.
authors.forename: Romualdo
authors.initials: R
authors.lastname: Barroso-Sousa
authors.affiliation: Instituto do Câncer do Estado de São Paulo (ICESP), Faculdade de Medicina, Universidade de São Paulo, Av Dr Arnaldo, 251, 5o andar, 01246-000 São Paulo, SP, Brazil.
authors.forename: Danilo D A Fonseca Reis
authors.initials: DD
authors.lastname: Silva
authors.affiliation: Instituto do Câncer do Estado de São Paulo (ICESP), Faculdade de Medicina, Universidade de São Paulo, Av Dr Arnaldo, 251, 5o andar, 01246-000 São Paulo, SP, Brazil.
authors.forename: Joao Victor Machado
authors.initials: JV
authors.lastname: Alessi
authors.affiliation: Instituto do Câncer do Estado de São Paulo (ICESP), Faculdade de Medicina, Universidade de São Paulo, Av Dr Arnaldo, 251, 5o andar, 01246-000 São Paulo, SP, Brazil.
authors.forename: Max Senna
authors.initials: MS
authors.lastname: Mano
keywords: aromatase inhibitors; breast neoplasm; endocrine therapy; locally advanced breast cancer; luminal breast cancer; neoadjuvant therapy
references.citation: Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004272
references.pmid: 16437480
references.citation: Clin Breast Cancer. 2011 Aug;11(4):246-51
references.pmid: 21737354
references.citation: J Clin Oncol. 2010 Jan 20;28(3):509-18
references.pmid: 19949017
references.citation: J Natl Cancer Inst. 2005 Feb 2;97(3):188-94
references.pmid: 15687361
references.citation: J Clin Oncol. 2005 Oct 20;23(30):7721-35
references.pmid: 16234531
references.citation: Cancer. 2005 Jun 1;103(11):2241-51
references.pmid: 15844176
references.citation: Nat Rev Drug Discov. 2015 Feb;14(2):130-46
references.pmid: 25633797
references.citation: N Engl J Med. 2012 Feb 9;366(6):520-9
references.pmid: 22149876
references.citation: Ann Oncol. 2014 Dec;25(12 ):2357-62
references.pmid: 25231953
references.citation: Int J Cancer. 1983 Jan 15;31(1):13-20
references.pmid: 6339421
references.citation: N Engl J Med. 2014 Jul 10;371(2):107-18
references.pmid: 24881463
references.citation: Lancet. 2012 Feb 4;379(9814):432-44
references.pmid: 22152853
references.citation: J Clin Oncol. 2001 Sep 15;19(18):3808-16
references.pmid: 11559718
references.citation: Trials. 2013 Aug 19;14:261
references.pmid: 23958221
references.citation: Int J Clin Oncol. 2014 Aug;19(4):607-13
references.pmid: 24101215
references.citation: Lancet Oncol. 2011 Jul;12(7):631-41
references.pmid: 21641868
references.citation: Nature. 2015 Jul 16;523(7560):313-7
references.pmid: 26153859
references.citation: Lancet. 2002 Jun 22;359(9324):2131-9
references.pmid: 12090977
references.citation: Ann Oncol. 2003 May;14(5):693-8
references.pmid: 12702521
references.citation: Clin Transl Oncol. 2012 Feb;14(2):125-31
references.pmid: 22301401
references.citation: Ann Oncol. 2001 Nov;12(11):1527-32
references.pmid: 11822750
references.citation: Breast Cancer Res Treat. 2014 Apr;144(3):569-76
references.pmid: 24562823
references.citation: Lancet. 2011 Aug 27;378(9793):771-84
references.pmid: 21802721
references.citation: Br Med J (Clin Res Ed). 1982 Mar 20;284(6319):869-70
references.pmid: 6802332
references.citation: Breast. 2013 Dec;22(6):1009-18
references.pmid: 24144949
references.citation: Nat Rev Clin Oncol. 2015 Mar;12(3):147-62
references.pmid: 25668732
references.citation: J Clin Oncol. 2009 Jun 1;27(16):2630-7
references.pmid: 19380449
references.citation: Breast Cancer Res Treat. 2007;105 Suppl 1:33-43
references.pmid: 17912634
references.citation: Future Oncol. 2015;11(10):1555-65
references.pmid: 25963432
references.citation: Lancet. 2014 Jul 12;384(9938):164-72
references.pmid: 24529560
references.citation: J Am Coll Surg. 2009 May;208(5):906-14; discussion 915-6
references.pmid: 19476859
references.citation: J Clin Oncol. 2005 Aug 1;23(22):5108-16
references.pmid: 15998903
references.citation: Eur J Cancer. 2014 Sep;50(13):2190-200
references.pmid: 24970786
references.citation: Clin Cancer Res. 2006 Feb 1;12(3 Pt 2):1024s-1030s
references.pmid: 16467120
references.citation: J Clin Oncol. 2011 Jun 10;29(17 ):2342-9
references.pmid: 21555689
references.citation: J Clin Oncol. 1997 Jul;15(7):2483-93
references.pmid: 9215816
references.citation: J Clin Oncol. 2006 Aug 10;24(23):3726-34
references.pmid: 16720680
references.citation: N Engl J Med. 2005 Dec 29;353(26):2747-57
references.pmid: 16382061
references.citation: J Clin Oncol. 2015 Jul 10;33(20):2270-8
references.pmid: 26033813
references.citation: Ecancermedicalscience. 2015 Mar 31;9:518
references.pmid: 25932042
references.citation: Ann Oncol. 2012 Dec;23(12):3069-74
references.pmid: 22674146
references.citation: Nat Rev Clin Oncol. 2012 Feb 28;9(4):223-9
references.pmid: 22371132
references.citation: Semin Radiat Oncol. 2009 Oct;19(4):195-203
references.pmid: 19732683
references.citation: Lancet Oncol. 2011 Nov;12(12):1101-8
references.pmid: 22018631
references.citation: Breast Cancer Res Treat. 2009 Jan;113(1):145-51
references.pmid: 18264759
references.citation: Cancer. 2006 May 15;106(10):2095-103
references.pmid: 16598749
references.citation: Nature. 2012 Oct 4;490(7418):61-70
references.pmid: 23000897
references.citation: J Clin Oncol. 2014 Jul 1;32(19):2010-7
references.pmid: 24868022
references.citation: Cancer Chemother Pharmacol. 2009 Jan;63(2):261-6
references.pmid: 18365197
references.citation: BMC Cancer. 2008 Feb 26;8:62
references.pmid: 18302747
references.citation: J Natl Cancer Inst. 2008 Oct 1;100(19):1380-8
references.pmid: 18812550
references.citation: Lancet Oncol. 2012 Apr;13(4):345-52
references.pmid: 22265697
references.citation: J Natl Cancer Inst. 2007 Jan 17;99(2):167-70
references.pmid: 17228000
references.citation: J Clin Oncol. 2013 Apr 10;31(11):1398-404
references.pmid: 23358971
references.citation: Lancet Oncol. 2015 Jan;16(1):25-35
references.pmid: 25524798
references.citation: Cancer. 2007 Jul 15;110(2):244-54
references.pmid: 17538978
references.citation: J Clin Oncol. 2007 Oct 20;25(30):4772-8
references.pmid: 17876012
references.citation: Lancet Oncol. 2010 Jan;11(1):55-65
references.pmid: 20005174
references.citation: Lancet. 2005 May 14-20;365(9472):1687-717
references.pmid: 15894097
references.citation: J Clin Oncol. 2011 Oct 10;29(29):3877-84
references.pmid: 21911726
references.citation: Breast Cancer Res Treat. 2012 May;133(1):237-46
references.pmid: 22286314
references.citation: Cancer Res. 2003 Oct 1;63(19):6523-31
references.pmid: 14559846
references.citation: Ann Oncol. 2013 Oct;24 Suppl 6:vi7-23
references.pmid: 23970019
references.citation: J Natl Cancer Inst Monogr. 2011;2011(43):120-3
references.pmid: 22043057
references.citation: Nat Rev Cancer. 2015 May;15(5):261-75
references.pmid: 25907219
references.citation: Breast Cancer Res Treat. 2014 Dec;148(3):581-90
references.pmid: 25395314
references.citation: J Natl Cancer Inst. 2014 Jan;106(1):djt337
references.pmid: 24317176
references.citation: N Engl J Med. 2015 Nov 19;373(21):2005-14
references.pmid: 26412349